These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Efficiency of seasonal influenza vaccine in persons older than 65 in Romania. Pilot case-control study I-MOVE, 2008-2009]. Piţigoi D; Lupulescu E; Alexandrescu V; Băeţel A; Sbârcea C; Ioniţă E; Săvulescu C; Duca E; Sima C; Truică C; Ibram S; Bobîrnac A; Militaru L; Arion M Bacteriol Virusol Parazitol Epidemiol; 2009; 54(2):109-16. PubMed ID: 20422925 [TBL] [Abstract][Full Text] [Related]
4. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Kissling E; Valenciano M; Larrauri A; Oroszi B; Cohen JM; Nunes B; Pitigoi D; Rizzo C; Rebolledo J; Paradowska-Stankiewicz I; Jiménez-Jorge S; Horváth JK; Daviaud I; Guiomar R; Necula G; Bella A; O'Donnell J; Głuchowska M; Ciancio BC; Nicoll A; Moren A Euro Surveill; 2013 Jan; 18(5):. PubMed ID: 23399425 [TBL] [Abstract][Full Text] [Related]
5. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. Rondy M; Larrauri A; Casado I; Alfonsi V; Pitigoi D; Launay O; Syrjänen RK; Gefenaite G; Machado A; Vučina VV; Horváth JK; Paradowska-Stankiewicz I; Marbus SD; Gherasim A; Díaz-González JA; Rizzo C; Ivanciuc AE; Galtier F; Ikonen N; Mickiene A; Gomez V; Kurečić Filipović S; Ferenczi A; Korcinska MR; van Gageldonk-Lafeber R; ; Valenciano M Euro Surveill; 2017 Jul; 22(30):. PubMed ID: 28797322 [TBL] [Abstract][Full Text] [Related]
6. First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States. Valenciano M; Ciancio B; Moren A; Euro Surveill; 2008 Oct; 13(43):. PubMed ID: 18947520 [TBL] [Abstract][Full Text] [Related]
7. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Kissling E; Valenciano M; Buchholz U; Larrauri A; Cohen JM; Nunes B; Rogalska J; Pitigoi D; Paradowska-Stankiewicz I; Reuss A; Jiménez-Jorge S; Daviaud I; Guiomar R; O'Donnell J; Necula G; Głuchowska M; Moren A Euro Surveill; 2014 Feb; 19(6):. PubMed ID: 24556348 [TBL] [Abstract][Full Text] [Related]
8. The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2). Valenciano M; Kissling E; Reuss A; Jiménez-Jorge S; Horváth JK; Donnell JM; Pitigoi D; Machado A; Pozo F; Vaccine; 2015 Jun; 33(24):2813-22. PubMed ID: 25936723 [TBL] [Abstract][Full Text] [Related]
9. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study. Kissling E; Valenciano M; Euro Surveill; 2011 Mar; 16(11):. PubMed ID: 21435329 [TBL] [Abstract][Full Text] [Related]
10. Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010. Savulescu C; Jiménez-Jorge S; de Mateo S; Pozo F; Casas I; Breña PP; Galmés A; Vanrell JM; Rodriguez C; Vega T; Martinez A; Torner N; Ramos JM; Serrano MC; Castilla J; Cenoz MG; Altzibar JM; Arteagoitia JM; Quiñones C; Perucha M; Larrauri A BMC Public Health; 2011 Nov; 11():899. PubMed ID: 22129083 [TBL] [Abstract][Full Text] [Related]
12. 2011-12 seasonal influenza vaccines effectiveness against confirmed A(H3N2) influenza hospitalisation: pooled analysis from a European network of hospitals. A pilot study. Rondy M; Puig-Barbera J; Launay O; Duval X; Castilla J; Guevara M; Costanzo S; de Gaetano Donati K; Moren A PLoS One; 2013; 8(4):e59681. PubMed ID: 23565159 [TBL] [Abstract][Full Text] [Related]
13. 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. Kissling E; Valenciano M; Pozo F; Vilcu AM; Reuss A; Rizzo C; Larrauri A; Horváth JK; Brytting M; Domegan L; Korczyńska M; Meijer A; Machado A; Ivanciuc A; Višekruna Vučina V; van der Werf S; Schweiger B; Bella A; Gherasim A; Ferenczi A; Zakikhany K; O Donnell J; Paradowska-Stankiewicz I; Dijkstra F; Guiomar R; Lazar M; Kurečić Filipović S; Johansen K; Moren A; Influenza Other Respir Viruses; 2018 Jul; 12(4):423-437. PubMed ID: 29125681 [TBL] [Abstract][Full Text] [Related]
14. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals. Rondy M; Launay O; Puig-Barberà J; Gefenaite G; Castilla J; de Gaetano Donati K; Galtier F; Hak E; Guevara M; Costanzo S; ; Moren A Euro Surveill; 2015 Jan; 20(2):. PubMed ID: 25613779 [TBL] [Abstract][Full Text] [Related]
15. I-MOVE: a European network to measure the effectiveness of influenza vaccines. Valenciano M; Ciancio B; Euro Surveill; 2012 Sep; 17(39):. PubMed ID: 23041022 [TBL] [Abstract][Full Text] [Related]
16. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. Valenciano M; Kissling E; Reuss A; Rizzo C; Gherasim A; Horváth JK; Domegan L; Pitigoi D; Machado A; Paradowska-Stankiewicz IA; Bella A; Larrauri A; Ferenczi A; ; Lazar M; Pechirra P; Korczyńska MR; Pozo F; Moren A; Euro Surveill; 2016; 21(7):pii=30139. PubMed ID: 26924024 [TBL] [Abstract][Full Text] [Related]
17. Strengths and limitations of assessing influenza vaccine effectiveness using routinely collected, passive surveillance data in Ontario, Canada, 2007 to 2012: balancing efficiency versus quality. Savage RD; Winter AL; Rosella LC; Olsha R; Gubbay JB; Skowronski DM; Crowcroft NS Euro Surveill; 2015 Apr; 20(16):. PubMed ID: 25953275 [TBL] [Abstract][Full Text] [Related]
18. Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season. Puig-Barberà J; Guglieri-López B; Tortajada-Girbés M; López-Labrador FX; Carballido-Fernández M; Mollar-Maseres J; Schwarz-Chavarri G; Baselga-Moreno V; Mira-Iglesias A; Díez-Domingo J; Vaccine; 2017 Dec; 35(52):7331-7338. PubMed ID: 29128380 [TBL] [Abstract][Full Text] [Related]
19. Vaccine effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine. Rose AMC; Kissling E; Gherasim A; Casado I; Bella A; Launay O; Lazăr M; Marbus S; Kuliese M; Syrjänen R; Machado A; Kurečić Filipović S; Larrauri A; Castilla J; Alfonsi V; Galtier F; Ivanciuc A; Meijer A; Mickiene A; Ikonen N; Gómez V; Lovrić Makarić Z; Moren A; Valenciano M; Influenza Other Respir Viruses; 2020 May; 14(3):302-310. PubMed ID: 32022450 [TBL] [Abstract][Full Text] [Related]
20. Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform. Stuurman AL; Carmona A; Biccler J; Descamps A; Levi M; Baum U; Mira-Iglesias A; Bellino S; Hoang U; de Lusignan S; Bonaiuti R; Lina B; Rizzo C; Nohynek H; Díez-Domingo J; Front Public Health; 2023; 11():1195409. PubMed ID: 37546295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]